New data from the Nordic Myeloma Study Group

Best Practice Nordic | Jun 2019 | EHA 2019 |

The Nordic Myeloma Study Group (NMSG) initiated the CARFI trial, an open randomized phase II study, to investigate the efficacy and safety of carfilzomib as part of induction and conditioning in salvage ASCT and to evaluate the role of carfilzomib/dexamethasone maintenance after salvage ASCT. In this MEDtalk Henrik Gregersen report that maintenance therapy with carfilzomib and dexamethasone maintenance prolongs median time to progression with approximately 6 months following salvage ASCT in multiple myeloma.